Results 191 to 200 of about 659,210 (249)

5′tRF‐GlyGCC Promotes Breast Cancer Progression via LDHA‐Mediated Glycolysis and Macrophage Polarization

open access: yesAdvanced Science, EarlyView.
5’tRF‐GlyGCC promotes breast cancer malignancy by binding to LDHA. This interaction, facilitated by FGFR1 and LDHA phosphorylation, enhances glycolysis. Additionally, 5’tRF‐GlyGCC/LDHA signaling recruits and polarizes macrophages into a pro‐tumor M2 state via CCL7, thus remodeling the tumor microenvironment.
Cheng Yi   +17 more
wiley   +1 more source

Population‐Based Multi‐Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease

open access: yesAdvanced Science, EarlyView.
Psoriatic disease (PsD) is a chronic skin disease, with challenges in early risk stratification and drug development. Through gene‐level causal inference framework and expression level validation, combined with longitudinal cohort study, CDSN and PRSS8 have been identified as candidate biomarkers and therapeutic targets for PsD.
Tianxing Wu   +13 more
wiley   +1 more source

Insect I‐Type Lysozymes Function as Antiviral Proteases by Forming Biomolecular Condensates

open access: yesAdvanced Science, EarlyView.
Upon rice viral infection, the insect vector activates the Toll–MyD88–Dorsal signaling cascade, inducing i‐type lysozyme (Lyz‐I1) expression. Lyz‐I1 functions as an antiviral protease through its conserved catalytic dyad Glu/Asp (E/D), mediating cleavage of viral proteins at specific Lys (K) residues.
Yu Du   +5 more
wiley   +1 more source

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

open access: yesAdvanced Science, EarlyView.
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley   +1 more source

Home - About - Disclaimer - Privacy